Nasvax Advances Most in Three Months on Trial of Liver Treatment

Nasvax Ltd. rose the most in almost three months after its parent company Biomedix Incubator Ltd. said Nasvax’s Phase 2a clinical trial of a treatment for fatty liver was successful.

Nasvax shares climbed as much as 8.9 percent, the biggest intraday gain since Dec. 27, to 1.63 shekels. They traded 2.3 percent higher at 1.53 shekels as of 11:24 a.m. in Tel Aviv. Biomedix increased 3.6 percent to 0.607 shekel.